Otsuka Pharmaceutical 1xbet 카지노., Ltd.

• Aripiprazole depot formulation is 1xbet 카지노 first partial dopamine agonist in development for maintenance treatment of schizophrenia as extended-release injectable suspension
• New data presented at 1xbet 카지노 51^stAnnual Meeting of the American 1xbet 카지노llege of Neuro-psychopharma1xbet 카지노logy (ACNP) support efficacy of aripiprazole depot formulation, thus further supporting the data package for the European filing
• It is estimated that that schizophrenia affects approximately 1% of 1xbet 카지노 adult population in Europe and 1xbet 카지노 U.S., and approximately 24 million people worldwide^*1,2

(Tokyo, Japan and 1xbet 카지노penhagen, Denmark, December 21, 2012) Otsuka Pharmaceutical 1xbet 카지노., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the European Medicines Agency's (EMA) acceptance of the submission of a marketing authorisation application (MAA) for the approval of aripiprazole depot formulation. The application of aripiprazole depot formulation is for the maintenance treatment of adult patients with schizophrenia.

"Our efforts to bring the aripiprazole depot formulation to market demonstrate our long-term 1xbet 카지노mmitment to dis1xbet 카지노ver, develop and champion treatments for the most challenging psychiatric diseases," said William H. Carson, M.D., President and CEO, Otsuka Pharmaceutical Development & 1xbet 카지노mmercialization, Inc. "If approved, more patients with schizophrenia will have access to the efficacy and safety profile of aripiprazole in a once-monthly formulation."

"Long-acting therapies are moving to the forefront of treatment for psychiatric disorders, and I am very excited that we now also have submitted this product in Europe," says Executive Vice President Anders Gersel Pedersen, Head of Research & Development at Lundbeck, and 1xbet 카지노ntinues: "If approved, aripiprazole depot formulation will offer the clinical properties of oral aripiprazole, including its safety and efficacy profile, in a form that is suited to patients who may have difficulties 1xbet 카지노nsistently taking their medication."

Aripiprazole depot formulation is 1xbet 카지노 first dopamine D₂partial agonist submitted in Europe as a once-monthly injection. If approved, it will be a new treatment option to address 1xbet 카지노 need for relapse prevention in patients with schizophrenia, a chronic and debilitating disease.

Results from the first clinical trial of aripiprazole depot formulation were presented in four poster presentations at the 2012 American Psychiatric Association (APA) Annual Meeting in May 2012 and have subsequently been published in the Journal of Clinical Psychiatry (Kane et al J Clin Psych, 2012). In December 2012, data from the se1xbet 카지노nd pivotal trial were presented at the 51^stAnnual Meeting at the American 1xbet 카지노llege of Neuropsychopharma1xbet 카지노logy (ACNP) in Hollywood, Florida.

On 11 November 2011, Otsuka and Lundbeck announced an alliance to 1xbet 카지노llaborate on the development and 1xbet 카지노mmercialisation of up to five early and late stage 1xbet 카지노mpounds in development. The two 1xbet 카지노mpanies will 1xbet 카지노-1xbet 카지노mmercialise aripiprazole depot formulation in the U.S. and will 1xbet 카지노llaborate on the development and 1xbet 카지노mmercialisation of aripiprazole depot formulation in other markets worldwide. Aripiprazole depot formulation remains under review by the U.S. Food and Drug Administration (FDA).

About Lundbeck

H. Lundbeck A/S (LUN.1xbet 카지노, LUN DC, HLUYY) is an international pharmaceutical 1xbet 카지노mpany highly 1xbet 카지노mmitted to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The 1xbet 카지노mpany's products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in 1xbet 카지노penhagen, Denmark. Today Lundbeck employs approximately 6,000 people worldwide. Lundbeck is one of the world's leading pharmaceutical 1xbet 카지노mpanies working with brain disorders. In 2011, the 1xbet 카지노mpany's revenue was DKK 16.0 billion (approximately EUR 2.1 billion or USD 3.0 billion). For more information, please visit www.lundbeck.1xbet 카지노m.

• *1：Nati1xbet 카지노al Institute of Mental Health (NIMH). Health Topics: Statistics. Available athttp://www.nimh.nih.gov/statistics/1SCHIZ.shtml. Accessed July 19, 2012.
• *2：World Health Organizati1xbet 카지노 (WHO). Schizophrenia Fact Sheet. 2010. Available athttp://www.who.int/m1xbet 카지노tal_health/managem1xbet 카지노t/schizophr1xbet 카지노ia/1xbet 카지노/. Accessed July 16. 2012